DiognosisMedication class guides
Back to Diognosis Data views

Medication Class Interaction Guides

High-yield Diognosis starting points for common medication groups and known interaction patterns: pharmacogenomics, CYP inhibition or induction, active metabolites, transporters, bleeding, QT, electrolytes, acid suppression, and PK exposure.

1549 drugs 11 class guides 85 validated examples 503 evidence entries Static examples; no runtime uploads

Scale-first grouping. These guides prioritize classes many people actually use, not only rare high-severity specialist drugs. The first links are quick-start examples; each card then opens a longer set of known examples.

Scale lens: CDC/NCHS reports broad prescription-drug and office-visit drug-therapy use, with analgesics and antihyperlipidemic agents among frequent therapeutic classes; ClinCalc DrugStats adds recent MEPS-derived signals such as statin, GLP-1/GIP, SGLT2, and anticoagulant utilization. CDC/NCHS ยท ClinCalc DrugStats

Statins and Lipid Medicines

High-scale because statins are among the most common chronic medicines; CYP3A, OATP/BCRP transport, fibrates, boosters, macrolides, and azoles can shift muscle-toxicity risk.

myopathyCYP3A4OATP/BCRP

Blood Pressure and Heart Failure

Common chronic-care drugs can overlap through potassium, renal function, bradycardia, nitrate/PDE5 hypotension, NSAID blunting, and ACE/ARB/ARNI washout rules.

potassiumhypotensionrenal

Anticoagulants and Antiplatelets

High-value because bleeding risk, CYP2C9/VKORC1 context, NSAIDs, SSRIs, azoles, antiplatelet activation, and transporter effects can all overlap.

bleedingINRP-gp

Diabetes and Weight-Loss Medicines

Scale is rising across metformin, insulin, SGLT2 inhibitors, GLP-1/GIP agents, and common cardiovascular co-meds; useful checks include hypoglycemia masking, metformin exposure, and warfarin changes.

metforminhypoglycemiaGLP-1/GIP

Pain, Inflammation, and Migraine

High-scale because NSAIDs, acetaminophen, opioids, tramadol, migraine medicines, and OTC pain relievers often meet anticoagulants, antidepressants, lithium, methotrexate, and kidney-risk drugs.

bleedingCYP2D6renal

Psychiatry, Neurology, Sleep, and OTC Sedating Medicines

Useful for CYP2D6 and CYP2C19 phenotype shifts, QT stacking, serotonin toxicity, anticholinergic burden, seizure threshold, sleep aids, and active-metabolite exceptions.

serotoninburdenCYP2D6

Antibiotics, Antifungals, and Antivirals

Often interaction-heavy because azoles, macrolides, rifamycins, boosters, and antivirals can strongly inhibit or induce CYP3A4, CYP2C9, P-gp, OATP, or absorption pathways.

CYP3A4CYP2C9P-gp

Acid Suppression, GI, Minerals, and Binding Interactions

Scale matters because PPIs, H2 blockers, antacids, iron, calcium, binders, thyroid hormone, and antibiotics are common; many misses are absorption/timing rather than CYP.

absorptiontimingminerals

Contraception, Hormones, and Reproductive Health

High-scale because contraceptives and hormone therapies are common and interaction outcomes include contraceptive failure, seizure destabilization, hormone exposure shifts, and perioperative counseling.

contraceptioninductionpregnancy

QT Risk, Antiarrhythmics, and Rate Control

Prioritizes narrow-therapeutic-index exposure, QT stacking, CYP2D6 antiarrhythmic metabolism, macrolide or azole inhibition, bradycardia, and electrolyte-sensitive combinations.

QTNTICYP2D6

Oncology, Immunology, and Transplant

Not the highest-scale outpatient group, but still kept because many drugs have narrow therapeutic windows, prodrug activation, transporter relevance, genotype actionability, and severe inducer sensitivity.

NTIactive metabolitesPGx